Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

reddy holding gmbh - treprostinil sodium - eq. treprostinil 5 mg/ml - solution for infusion - 5 mg/ml - treprostinil sodium - treprostinil

Canada - English - Health Canada

dr reddy's laboratories ltd - treprostinil (treprostinil sodium) - solution - 5mg - treprostinil (treprostinil sodium) 5mg

Ireland - English - HPRA (Health Products Regulatory Authority)

tillomed pharma gmbh - treprostinil - solution for infusion - treprostinil

Canada - English - Health Canada

dr reddy's laboratories ltd - treprostinil (treprostinil sodium) - solution - 2.5mg - treprostinil (treprostinil sodium) 2.5mg

Ireland - English - HPRA (Health Products Regulatory Authority)

reddy holding gmbh - treprostinil - solution for infusion - treprostinil

Ireland - English - HPRA (Health Products Regulatory Authority)

tillomed pharma gmbh - treprostinil - solution for infusion - treprostinil

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - treprostinil (unii: rum6k67esg) (treprostinil - unii:rum6k67esg) - treprostinil injection is indicated for the treatment of pulmonary arterial hypertension (pah; who group 1) to diminish symptoms associated with exercise. studies establishing effectiveness included patients with nyha functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (58%), pah associated with congenital systemic-to-pulmonary shunts (23%), or pah associated with connective tissue diseases (19%) [see clinical studies (14.1)] . in patients with pah requiring transition from epoprostenol, treprostinil injection is indicated to diminish the rate of clinical deterioration. consider the risks and benefits of each drug prior to transition. none risk summary limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. however, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see clinical considerations) . in animal studies, no adverse reproductive and developmental

Canada - English - Health Canada

dr reddy's laboratories ltd - treprostinil (treprostinil sodium) - solution - 1mg - treprostinil (treprostinil sodium) 1mg

Canada - English - Health Canada

dr reddy's laboratories ltd - treprostinil (treprostinil sodium) - solution - 10mg - treprostinil (treprostinil sodium) 10mg

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - treprostinil (unii: rum6k67esg) (treprostinil - unii:rum6k67esg) - treprostinil is indicated for the treatment of pulmonary arterial hypertension (pah; who group 1) to diminish symptoms associated with exercise. studies establishing effectiveness included patients with nyha functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (58%), pah associated with congenital systemic-to -pulmonary shunts (23%), or pah associated with connective tissue diseases (19%) [see clinical studies (14.1) ]. in patients with pah requiring transition from epoprostenol, treprostinil is indicated to diminish the rate of clinical deterioration. consider the risks and benefits of each drug prior to transition. none risk summary limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. however, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see clinical considerations) . in animal studies, no adverse reproductive and developmental effects were seen